Product
ALLO-501A
2 clinical trials
2 drugs
3 indications
Indication
Large B Cell LymphomaIndication
Chronic Lymphocytic LeukemiaDrug
ALLO-501Drug
ALLO-501AClinical trial
A Randomized, Open-Label, Phase 2 Study Evaluating Lymphodepletion With ALLO-647, Fludarabine, and Cyclophosphamide, vs. Fludarabine and Cyclophosphamide Alone, in Subjects With Relapsed/Refractory Large B-Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell TherapyStatus: Recruiting, Estimated PCD: 2025-04-01
Clinical trial
A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-501A, an Anti-CD19 Allogeneic CAR T Cell Therapy, and ALLO-647, an Anti-CD52 Monoclonal Antibody, in Subjects With Relapsed/Refractory Large B-Cell Lymphoma (LBCL)Status: Recruiting, Estimated PCD: 2025-01-01